Rosen Law Firm Urges AstraZeneca Investors to Act Before February 21 Deadline

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) --

IMPORTANT NOTICE: The Rosen Law Firm, a prominent global law firm dedicated to protecting investor rights, is reminding investors who purchased securities of AstraZeneca PLC (NASDAQ: AZN) during the period from February 23, 2022, through December 17, 2024 (the "Class Period"), about the approaching deadline of February 21, 2025, for lead plaintiff applications in a securities class action that was initially filed by the Firm.

WHAT THIS MEANS: If you bought AstraZeneca securities during the Class Period, you may be eligible to pursue compensation without having to pay any upfront legal fees. This is possible through a contingency fee system, where attorneys only get paid if the case is successful.

NEXT STEPS: If you wish to be part of the AstraZeneca class action, you can sign up at this link or reach out to Phillip Kim, Esq. by phone at 866-767-3653, or through email at [email protected] for further information regarding the proceedings. Remember, a class action lawsuit has already been initiated, and if you aim to become the lead plaintiff, it is critical to file your motion with the Court by no later than February 21, 2025. The lead plaintiff will represent other investors in managing the case.

WHY CHOOSE ROSEN LAW FIRM: It is crucial for investors to select highly qualified legal counsel. The Rosen Law Firm has a strong history of achieving favorable outcomes in securities litigation, setting it apart from firms that may lack the necessary experience or resources. Many so-called legal firms simply act as intermediaries without having the capability to litigate these cases effectively. The Rosen Law Firm has represented clients globally, with a dedicated focus on securities class actions and related legal matters. The firm has successfully achieved noteworthy settlements, including the largest securities class action settlement involving a Chinese entity during its peak. In 2017, Rosen Law Firm was recognized as the leader in the number of securities class action settlements, continuing this trend to remain in the top four rankings from 2013 onwards, recovering hundreds of millions for investors. In 2019, they secured over $438 million for investors, and their founding partner has been celebrated as a significant figure in the plaintiffs' bar.

CASE DETAILS: The lawsuit alleges that throughout the Class Period, AstraZeneca made significant false statements or failed to disclose critical information related to its business operations. Specifically, it is claimed that AstraZeneca was involved in insurance fraud in China, which led to increased legal troubles that included the detention of its China President by local authorities. This situation meant that AstraZeneca was not fully transparent about its legal risks, potentially jeopardizing its business in China. When these facts were eventually revealed, the lawsuit asserts that investors experienced considerable financial losses.

To seize the opportunity to join the AstraZeneca class action, visit this link, call Phillip Kim, Esq. at 866-767-3653, or write to [email protected] for more specific details.

ADDITIONAL INFORMATION: Please be advised that until a class is officially certified, individuals are not represented by counsel unless they specifically retain one. Investors are free to choose their own legal counsel or can remain passive at this time without any immediate requirement to act. Importantly, an investor’s chance of participating in any future recovery does not depend on their role as lead plaintiff.

Stay informed by following the firm on LinkedIn for updates on this situation.

lawfirm, securities, classaction